P
PRME
vs
S&P 500
S&P 500
Over the past 12 months, PRME has significantly outperformed S&P 500, delivering a return of +47% compared to the S&P 500's +16% growth.
Stocks Performance
PRME vs S&P 500
Performance Gap
PRME vs S&P 500
Performance By Year
PRME vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Prime Medicine Inc
Glance View
Prime Medicine Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2022-10-20. Prime Medicine, Inc. is a United States-based biotechnology company. The firm is engaged in multiple drug discovery programs that target liver, eye, ex-vivo hematopoietic stem cell and neuro-muscular indications. The firm's Prime Editing, a transformative technology that addressed the cause of genetic disease. The firm's collaborative approach help fight disease and accelerating the development of Prime Editing to deliver therapies for patients. Its Prime Editing is used to modify gene-regulatory sequences. These edits can be made in therapeutically relevant cells and organs, including specialized terminally differentiated cells. Its Prime Editing acts as a Deoxyribonucleic acid (DNA) word processor, with the power to search and replace genetic sequences at their exact location in the genome, all without making double-strand breaks in DNA.